It is well known that MVA 1 is required for growth of mammalian cells (1-4) as well as constituting the key metabolite in the biosynthesis of cholesterol and a variety of nonsterol isoprenoid derivatives (e.g. dolichyl-phosphate, farnesyl pyrophosphate, isopentenyladenine, and ubiquinone). The formation of MVA from HMG-CoA, which is catalyzed by HMG-CoA reductase, is the principal regulatory step in the pathway (1). Increasing evidence suggests that the MVA-derived product critical for cell growth is an isoprene of nonsterol type (1-4).
were from Amersham Corp.
Cell Culture-The human melanoma cell line SK-MEL-2, human colon carcinoma cells (line WiDr), and the human hepatoblastoma cell line HepG2 were obtained from American Type Culture Collection. SK-MEL-2 is derived from a metastasis of malignant melanoma and has been characterized in detail by Fogh and Trempe (8) . All three cell lines were cultured in monolayers in tissue culture flasks maintained in a 95% air, 5% CO 2 atmosphere at 37°C in a humidified incubator. Modified Eagle's medium supplemented with nonessential amino acids, glutamine, sodium pyruvate, bensylpenicillin, streptomycin, and 10% (v/v) fetal calf serum was used as the experimental medium. The cells were dense-subconfluent at the start of the experiments.
HMG-CoA Reductase Activity-Cells in 60-mm dishes were, after the indicated treatments, rinsed twice in PBS and harvested for assay of cellular HMG-CoA reductase activity essentially as described elsewhere (9) .
Synthesis of Dolichyl-phosphate-Cells in 175-cm 2 flasks were after experimental conditions labeled with [2] [3] [4] [5] [6] [7] [8] [9] [10] [11] [12] [13] [14] C]acetate (3.33 mCi/ml; 57 mCi/mmol) for 4 h. Isolation and purification of dolichyl-phosphates with reversed phase high performance liquid chromatography was performed following the description of Adair and Keller (10) . The radioactivity in fractions corresponding to dolichyl-phosphates (dolichyl-P-16 to dolichyl-P-22) was determined by scintillation counting and corrected for variation in the amount of cellular protein.
DNA Synthesis-DNA synthesis was assayed by measuring the incorporation of [ 3 H]thymidine (2 Ci/ml, 5 Ci/mmol) into acid-precipitable cell material as described elsewhere (7) .
Analysis of Receptor Gene Expression-Total RNA was isolated using the RNazol B method according to the description of the manufacturer. Reverse transcription of both IGF-1R and EGF-R mRNA was performed using 250 ng total RNA, 100 mM of each dNTP (Pharmacia Biotech Inc.), 20 units of RNasin (Boehringer Mannheim), 1.4 g of bovine serum albumin (DNase-RNase free, Pharmacia), 1 ϫ reverse transcriptase buffer (50 mM Tris-HCl, pH 8.3, 75 mM KCl, 3 mM MgCl 2 ), 200 units of reverse transcriptase (Superscript, Life Technologies, Inc.) and 30 pmol of downstream primer. Positive control template for the reverse transcription of the EGF-R was 200 ng of total RNA isolated from a breast cancer cell line (MDA-231) in which the EGF-R gene is overexpressed. The reaction was heated to 42°C for 1 h and then to 95°C for 15 min to inactivate the reverse transcriptase. From the published cDNA sequences of the normal human IGF-1R (11) and EGF-R (12), oligonucleotide primers for their tyrosine kinase domains were designed using OLIGO TM version 4.0 Primer Analysis Software (National Biosciences, Inc., Plymouth, MN) ( Table I) .
The primers were synthesized on an Applied Biosystems 381A DNA synthesizer using the standard phosphoamidite chemistry. PCR was carried out essentially as described by Saiki et al. (13) using a PerkinElmer thermal cycler. The amplification products were separated on an ethidium bromide-stained agarose gel.
Antisense Experiments-The antisense and sense oligonucleotides were synthesized on an Applied Biosystems model 381A DNA sythesizer with ␤-cyanoethyl phosphoamidite and tetraetylthiuram disulfide chemistry (14) . Antisense and sense oligonucleotides corresponding to human IGF-1R RNA nucleotides 2251-2269 of the putative prereceptor splicing site were synthesized as described previously (15) . Antisense or sense oligonucleotides were added to cultures of SK-MEL-2 cells at a concentration of 40 g/ml for 24 h.
Determination of Protein Synthesis-Overall protein synthesis was determined after labeling with [3,4(n)-
3 H]valine (1 Ci/ml, 30 Ci/mmol) by measuring the radioactivity in the acid-insoluble material as described elsewhere (7) . The values were corrected for variation in cellular protein.
Determination of N-Linked Glycosylation-Total incorporation of D-[6-
3 H]glucosamine (GlcN) (1 Ci/ml, 28.0 Ci/mmol) into acid-stable glycoproteins was determined according to the description of Carson and Lennarz (16) . The radioactivity was normalized to protein content.
Membrane Preparation-Preparation of cell membranes was performed essentially as described elsewhere (17 H]valine (40 Ci/ml valinefree medium) for 4 or 16 h were harvested and homogenized in a buffer containing 0.32 M sucrose, 1 mM taurodeoxycholic acid, 2 mM MgCl 2 , 1 mM EDTA, 25 mM benzamidine, 1 g/ml bacitracin, 2 mM phenylmethylsulfonyl fluoride, 10 g/ml aprotinin, 10 g/ml soya bean trypsin inhibitor, and 10 g/ml leupeptin.
After a 10-min centrifugation at 600 ϫ g at 4°C, the pellet, containing unbroken cells, nuclei, and cytoskeleton, was discarded. The supernatant was then centrifugated at 17,300 ϫ g for 30 min. The resulting pellet contained cell membranes, and the supernatant represented the intracellular compartment (excluding nuclei) containing ER, Golgi, and other organelles (18) .
Immunoprecipitation of IGF-1R-The prepared cell membranes (or the whole cells) were lyzed in 10 ml of ice-cold PBSTDS containing the aforementioned protease inhibitors. To 1 ml of material were added 15 l of Protein G Plus-Agarose and 1 g of ␣IR-3. After a 2-24-h incubation at 4°C on a rocker platform, the immunoprecipitates were collected by centrifugation in a microcentrifuge at 2,500 rpm for 15 min. The supernatant was discarded whereupon the pellet was washed 4 times with 1 ml of PBSTDS. The material was then dissolved in sample buffer and used for SDS-PAGE.
Initially we estimated the radioactivity of immunoprecipitated intracellular IGF-1R by subtracting the radioactivity of the precipitate from the whole cells to that of the precipitate from the cell membranes, which were isolated from parallel dishes. However, in later experiments we instead immunoprecipitated the 17,300 ϫ g supernatant (containing cytoplasm and organelles). This was done by adding one volume 2 ϫ PBSTDS to one volume of the supernatant and then using the same procedures as above. Both methods gave similar results. The amount of [ 3 H]valine-labeled IGF-1R in the intracellular compartment was 30 -40% of that in the cell membrane. It was confirmed by cross-linking with 125 I-IGF-1 that each fraction contained IGF-1R. 125 I-IGF-1 Binding Assay-Cells were cultured in 24-well plates (the well diameter was 15 mm). The outer wells were not used since the evaporational loss of medium was greater in those. The cells were subjected to different treatments, after which they were rinsed twice with ice-cold PBS and once with binding buffer (1 mM Hepes, pH 7.4, 1% bovine serum albumin, 135 mM NaCl, 4.8 mM KCl, 1.7 mM MgSO 4 , 2.5 mM CaCl 2 ⅐2H 2 O). Finally, each well was incubated with 500 l of binding buffer containing 30,000 dpm of 125 I-labeled IGF-1 (1,630 -2,800 Ci/mmol) for 30 min at 20°C. After the incubations the cells were rinsed once with PBS and then lyzed in a solution buffer (20 mM Hepes, 1% Triton-X, 10% glycerol, and 0.1% bovine serum albumin). The lysate was transferred to scintillation vials and counted in a Beckman LS 5000 TA counter. The unspecific binding, which was subtracted from the obtained experimental values, was determined by coincubation with unlabeled IGF-1 (1000 ng/ml).
Scatchard analysis was performed essentially identically to the binding assay except that it was run at 4°C. The binding time was 5 h. While the 125 I-IGF-1 concentration was constant the concentration of unlabeled ligand varied between 12.5 and 1000 ng/ml. The number of receptors/cell was calculated as described by Clark and Peck (19) .
Cross-linking of IGF-1R-Cells growing in 6-cm dishes were rinsed three times with ice-cold PBS and then incubated with 0.35 ϫ 10 6 dpm of 125 I-IGF-1/dish in the aforementioned binding buffer with the addition of 1 mg of bacitracin/ml for 2 h at 20°C. Cross-linking was then performed essentially as described by Gammeltoft et al. (20) . The crosslinked proteins were analyzed by SDS-PAGE (10% polyacrylamide).
SDS-PAGE-Immunoprecipitates or cross-linked samples (containing IGF-1R) were dissolved in a sample buffer containing 0.0625 M Tris-HCl, pH 6.8, 20% glycerol, 2% SDS, bromphenol blue, and dithiothreitol. Sample amounts obtained from 150 g of cell protein were analyzed by SDS-PAGE with a 4% stacking gel and a 5 or 10% separation gel essentially according to the protocol of Laemmli (21) . Molecular weight markers (Bio-Rad) were run simultaneously. The radioactivity was measured either using fluorography with Hyperfilm-MP TM (Amersham Corp.) after impregnating the gel with Amplify TM (Amersham Corp.), according to the description of the manufacturer, or by counting the radioactivity in gel slices. Hence, 2-mm gel slices were put into scintillation vials and dissolved in 0.5 ml of Soluene-350 (CanberraPackard, Meriden, CT). After a 3-h incubation at 50°C, 8 ml of scintillation mixture (Hionic Fluor TM , Canberra-Packard) was added, and the radioactivity was counted.
Western Blotting-Immunoprecipitated IGF-1R proteins were subjected to SDS-PAGE and then transferred overnight to nitrocellulose membranes (Hybond, Amersham Corp.). The membranes were subsequently blocked for 1 h at room temperature with a solution of 5% (w/v) skimmed milk powder and 0.02% (v/v) Tween 20 in PBS, pH 7.5. Glycoprotein Detection and Deglycosylation-Immunoprecipitated IGF-1R proteins isolated from SK-MEL-2 were subjected to SDS-PAGE (7.5%) and transferred to a nitrocellulose filter (see "Western Blotting" above). The filters were then cut in half and incubated in a digestion buffer (50 mM sodium phosphate, 5 mM EDTA, 10 g/ml leupeptin, and 10 g/ml aprotinin, pH 7.5) with or without 0.2 unit/ml of N-glycosidase F (Boehringer-Mannheim) for 24 h in room temperature at gentle agitation. N-Linked carbohydrates were subsequently detected with lectin MAA from the Dig Glycan Differentiation Kit (Boehringer-Mannheim) according to the description from the manufacturer.
Immunocytochemical Technique-The cells were fixed in a mixture of methanol and acetone (1:1 by volume) and then air-dried. A polyclonal IGF-1R antiserum (22) was applied overnight at ϩ4°C to ϩ 8°C. The antigen-antibody binding was visualized by the avidine-biotin-peroxidase complex technique (23) following the manufacturer's instructions (Vectastain, Vector Laboratories, Burlingame, CA). Diaminobenzidine and Mayer's hematoxylin were used as chromogen and for counterstaining, respectively.
Determination of Protein Content-Protein content of cell lysates was determined by a dye-binding assay (24) , with a reagent purchased from Bio-Rad. Bovine serum albumin was used as a standard.
RESULTS

Connection between MVA and Cell Growth: A Possible Role of N-Linked Glycosylation-The effect of lovastatin (3 M)
on HMG-CoA reductase activity, dolichyl-phosphate synthesis, and N-linked glycosylation in SK-MEL-2 cells was compared. As can be seen in Fig. 1A , the three events were depressed in the aforementioned order with respect to the time course as well as to the magnitude of the inhibitory effect. This correlation between the depression of the biosynthesis of the MVA product dolichyl-phosphate and the rate of N-linked glycosylation is expected, since de novo synthesized dolichyl-phosphate acts as a carrier of oligosaccharides in the assembly of glycoproteins in the lumen of the ER (5, 6) . After a 24-h lovastatin treatment the overall N-linked glycosylation of cellular proteins had become drastically decreased (Fig. 1, A and B) . In contrast, lovastatin caused only a slight depression of overall de novo synthesis of cellular proteins (Fig. 1, A and B) . Furthermore, as shown in Fig. 1C , there was only a slight decrease in de novo synthesized proteins localized in the cell membrane.
In Fig. 2 the time-course for how an inhibition of HMG-CoA reductase, obtained by 3 M lovastatin, depressed the proliferation of SK-MEL-2 cells is illustrated. After a 24-h treatment the cells were arrested. Lovastatin given at this low concentration was proven to be nontoxic to the cells even following incubations for several days (data not shown). However, treatment with lower concentrations of lovastatin than 3 M did not result in a complete growth arrest (data not shown). If MVA (0.77 mM) was present together with lovastatin growth arrest was completely prevented. In Fig. 2 it is also shown that arrested cells stimulated with MVA reinitiated DNA synthesis, but first after a lag period of 15 h. If tunicamycin-B (TM-B), a specific inhibitor of N-linked glycosylation (25) , was added along with MVA, the initiation of DNA synthesis was prevented ( Fig. 2) . It was confirmed that TM-B (when given at a dose of 1.2 M) did not depress the rate of de novo protein synthesis (data not shown).
A Potential Role of Growth Factor Receptor Expression in MVA-regulated Cell Growth-The extracellular domains of growth factor receptors usually contain N-glycosidically linked carbohydrates (11, 26) . Since inhibition of MVA synthesis leads to a decreased rate of N-linked glycosylation (cf. Fig. 1 , A and B), the possibility is raised that MVA may be rate-limiting for the receptor function. For instance, MVA-regulated glycosylation might be required for the translocation of growth factor receptor proteins from ER to the cell membrane. If this is the case, a suppression of HMG-CoA reductase activity would reduce the number of growth factor receptors at the cell surface. This would lead to a decreased number of receptor-ligand interactions, which in turn would decrease receptor-mediated signaling events (i.e. tyrosine phosporylation) and finally lead to growth arrest. Hypothetically, this inhibitory response would be delayed if increased concentrations of the appropriate ligand were administered. In Table II it is shown that neither bombesin, EGF, platelet-derived growth factor nor transform- ing growth factor ␤1 could counteract the growth inhibitory effect following inhibition of HMG-CoA reductase. In contrast, both insulin and IGF-1 caused a substantial, dose-dependent, counteractive effect. Whereas microgram doses of insulin were required, nanogram doses of IGF-1 were enough to achieve this effect. If insulin was added at concentrations below 100 ng/ml, no growth-stimulatory effect was seen (data not shown). Considered together with the previous finding that insulin added at supraphysiological concentrations can bind to IGF-1R (27) , the current results suggest that the growth-stimulatory effect of insulin on SK-MEL-2 cells may be mediated via IGF-1R (see also below). Addition of basic fibroblast growth factor also exerted a counteractive effect. However, compared to insulin and IGF-1, the effect of basic fibroblast growth factor was very weak (Table II) . The data in Table II are in line with the results obtained by Doyle et al. (28) . They demonstrated that high concentrations of insulin or IGF-1 delayed the growth arrest of HMG-CoA reductase inhibitors in chinese hamster ovary cells (28) .
In Fig. 3A it is confirmed by reverse transcription PCR that SK-MEL-2 cells express transcripts for IGF-1R (lane 1). In contrast, no mRNA coding for EGF-R was detected (lane 5) indicating that SK-MEL-2 cells express no or very little EGF-R. Using a monoclonal antibody (i.e. ␣IR-3) (29, 30) against the ␣-subunit (the extracellular and ligand-binding domain) of IGF-1R, the growth-stimulatory effect of both IGF-1 and insulin on lovastatin-treated SK-MEL-2 cells was abrogated, whereas control IgG (here a monoclonal antibody against the EGF-R) had no effect (Fig. 3B ). This finding strongly suggests that the mitogenic effect of IGF-1 on lovastatin-blocked cells requires the binding of IGF-1 to its receptor, and also further supports the idea that insulin exerts its growth-stimulatory effect by cross-binding to IGF-1R. Analysis of 125 I-IGF-1 binding confirmed that ␣IR-3 substantially decreased the number of IGF-1 binding sites (Fig. 3C) . In a separate experiment it was also shown that treatment with antisense oligonucleotides against IGF-1R mRNA decreased the IGF-1 binding in SK-MEL-2 cells (data not shown). It was also confirmed that the IGF-1 binding sites have different affinities for IGF-1 and insulin. Whereas 50 ng of IGF-1/ml caused a substantial displacement of 125 I-IGF-1, the equivalent dose of insulin had no effect. The number of IGF-1 binding sites in control SK-MEL-2 cells measured as much as 115,000/cell (data not shown). A similar expression of IGF-1R has also been observed in other melanoma cell lines (31) .
It has been confirmed elsewhere that IGF-1R contains Nglycosidically linked carbohydrates (11) . The ␣-subunit contains 11 possible glycosylation sites, whereas the ␤-subunit contains only 5 sites (11) . This means that the whole receptor, which is an ␣-␤-␤-␣ oligotetramer, may contain 32 glycosylation sites.
Expression of de Novo Synthesized IGF-1R Glycoproteins at the Cell Surface-To investigate whether a lowered HMG-CoA reductase activity affects the N-linked glycosylation and expression of IGF-1R at the cell surface, gelelectrophoretic analyses of radiolabeled proteins subjected to immunoprecipitation with ␣IR-3 were performed. ␣IR-3 is specific for the human IGF-1R and has been extensively used for immunoprecipitation (29, 32) . The antibody does not, or only very weakly, immunoprecipitate the insulin receptor (29) . The specificity of this assay is shown by fluorography after gel electrophoresis of the [ 3 H]valine-labeled ␣IR-3 immunoprecipitate (Fig. 4A) . As can be seen, the 130-and 96-kDa IGF-1R subunits appeared; however, not if the cell proteins were immunoprecipitated with an irrelevant antibody. The specificity of the 130-kDa product was further confirmed by Western blotting (Fig. 4B , left lane) using another antibody (N-20) which recognizes the ␣-subunit. After treatment of the immunoprecipitate with N-glycosidase F, which specifically removes N-linked oligosaccharides, the mobility of the ␣-subunit on the gel is increased (Fig. 4B, right  lane) . N-linked glycosylation of the 130-kDa subunit was con- 62,800 Ϯ 1,900 Insulin (10 g/ml)
193,600 Ϯ 29,000 IGF-1 (5 ng/ml) 55,700 Ϯ 6,700 IGF-1 (20 ng/ml) 105,200 Ϯ 12,700 IGF-1 (50 ng/ml) 197,200 Ϯ 7,900 PDGF (10 ng/ml) 4,300 Ϯ 0,400 PDGF (50 ng/ml) 4,800 Ϯ 1,200 TGF-␤1 (10 ng/ml) 3,400 Ϯ 0,500 TGF-␤1 (50 ng/ml) 3,200 Ϯ 0,500 a bFGF, basic fibroblast growth factor; PDGF, platelet-derived growth factor; TGF, transforming growth factor. firmed by lectin detection after transfer of the immunoprecipitate to a nitrocellulose filter (Fig. 4C) . Upon incubation of the filter with N-glycosidase F, no sugars were detected (Fig. 4C) . Taken together, the data presented in Fig. 4 , A-C, confirm that the ␣IR-3 immunoprecipitate consists of the N-linked glycosylated IGF-1R proteins.
Next we studied the effect of inhibition of HMG-CoA reductase activity on N-linked glycosylation and translocation of the IGF-1R proteins to the cell surface. Herewith the SK-MEL-2 cells either remained untreated or were exposed to lovastatin Since N-linked oligosaccharides are always added during protein synthesis (cotranslationally) (6, 33, 34) , IGF-1R proteins reaching the cell surface should consist of de novo synthesized glycoproteins. Analysis of the amount of de novo synthesized IGF-1R at the cell surface was carried out by measuring the [ 3 H]valine-labeled ␣IR-3-immunoprecipitable proteins in the cell membrane fraction. As has already been stated in Fig. 1, A and B (Fig. 4D, lower panel) . The cross-linking product had a molecular mass of 137-kDa (i.e. IGF-1 ϩ ␣-subunit of IGF-1R). As shown the amount of functional membrane IGF-1R was almost completely depleted after inhibition of HMG-CoA reductase. However, if MVA was present this depletion was efficiently abrogated. If TM-B was also present the effect of MVA was prevented. The specificity of the cross-linking assay was confirmed by coincubation with unlabeled IGF-1 which abolished the labeling of the receptors with ]valine labeling in 2-mm gel slices was assayed using scintillation counting (Fig. 4E) .
Distribution of de Novo Synthesized IGF-1R Proteins between the Intracellular Compartment and the Cell Surface-
The appearance of de novo synthesized IGF-1R in the intracellular compartment compared to that in the cell membrane was assayed by measuring immunoprecipitated [ 3 H]valine-labeled IGF-1R proteins in each compartment using the method shown in Fig. 4E . While de novo synthesized receptors at the cell membrane almost disappeared after a 24-h treatment with lovastatin or TM-B, the intracellular ones were only slightly depressed (approximately 30%) (Fig. 5A ). This finding may appear surprising since an intracellular accumulation of newly synthesized receptor proteins might be expected when the translocation to the cell surface is inhibited. Most likely our result is explained by the fact that underglycosylated proteins are degraded faster than are fully glycosylated proteins (34, 35) . Degradation of newly synthesized proteins has in fact been shown to occur in ER (36) . There was no difference in receptor distribution between control cells and cells given lovastatin and MVA. As shown, the effects of the different experimental conditions on the amount of de novo synthesized IGF-1R at the cell membrane correlated well with the corresponding effects on the 125 I-IGF-1 binding (Fig. 5, A and B) . Furthermore, the MVA-dependent changes in distribution of de novo synthesized IGF-1R shown in Fig. 5A are in concurrence with the IGF-1R distribution assayed by immunocytostaining (data not shown). Fig. 6A the kinetics of the expression of de novo synthesized IGF-1R following depletion and readdition of MVA are shown. The effect on both intracellular and cell membrane-bound receptor proteins are illustrated, and are to be compared with the effects on IGF-1 binding and DNA synthesis. As shown, the amount of de novo synthesized IGF-1R proteins, i.e. newly synthesized and glycosylated receptors, at the cell membrane was rapidly reduced after lovastatin addition (8 -24 h ). This correlated well to the simultaneous decrease in DNA synthesis. In contrast, in line with the data shown in Fig. 5A the intracellular levels of de novo synthesized IGF-1R proteins, i.e. newly synthesized but not glycosylated receptors, were only slightly depressed.
Kinetics of IGF-1R Expression following Depletion and Re-
When MVA was added after a 24-h HMG-CoA reductase inhibition, the IGF-1 binding increased within 8 h and was after a further 4 h fully restored (Fig. 6A) . This is consistent with the substantial increase in the amount of de novo synthesized receptor proteins at the cell membrane that was observed at this time. Thus, it seems evident that the translocation of functional (i.e. ligand-binding) IGF-1R molecules to the cell surface occurs prior to the initiation of DNA synthesis (Fig.  6A) . This was also confirmed in a separate experiment by cross-linking (Fig. 6B) . In this experiment treatment with MVA for 8 h was sufficient to increase the amount of functional IGF-1R drastically, whereas there was still no initiation of DNA synthesis.
By Scatchard plot analysis it was confirmed that inhibition of HMG-CoA reductase activity drastically decreases the number of IGF-1R (Fig. 7A) . The receptor number was restored upon a 24-h stimulation with MVA (Fig. 7A) . We also investigated the dose-response correlation between the increase in IGF-1 binding and DNA synthesis (Fig. 7B) . A MVA dose of 0.008 mM was not enough to induce any measurable increase in neither DNA synthesis nor IGF-1 binding. 0.077 mM MVA or higher doses, however, significantly increased both processes. Thus, there is a clear correlation of the MVA dose dependence between the increase in IGF-1 binding and initiation of DNA synthesis.
In order to further evaluate whether the expression of IGF-1R is necessary for the subsequent initiation of DNA synthesis we investigated the kinetics of the cell cycle dependence on IGF-1 binding in SK-MEL-2 cells. This was carried out by adding ␣IR-3 at different times after stimulation with MVA. The effect on DNA synthesis was assayed after [ 3 H]thymidine incorporation. As shown, in contrast to an irrelevant antibody (here anti-EGF-R), addition of ␣IR-3 at 0 or 5 h after stimulation completely prevented initiation of DNA synthesis (Fig. 8) . However, if ␣IR-3 was added after 10 h, initiation of DNA synthesis was not prevented. Since DNA synthesis is started after approximately 15 h in MVA-stimulated SK-MEL-2, our data strongly suggest that the preceding IGF-1R expression is necessary for G 1 /S progression. As can also be seen in Fig. 8 , the kinetics of the dependence on IGF-1 binding were very similar to the kinetics of the requirement for N-linked glycosylation. These data further support our notion that MVA induces cell growth through stimulating N-linked glycosylation of IGF-1R proteins.
Next we investigated whether inhibition of HMG-CoA reductase activity and N-linked glycosylation also could evoke downregulation of functional IGF-1R in other cell types. In Fig. 9 the effects of lovastatin and TM on the IGF-1 binding in hepatoblastoma cells and colon carcinoma cells are illustrated. In order to decrease the proliferation of these cell lines higher concentrations of lovastatin (10 and 100 M, respectively) were required compared to SK-MEL-2. As shown, there was a clear correlation between the decrease in DNA synthesis and 125 I-IGF-1 binding in both cell lines.
Finally, a simplified scheme showing the relationship between MVA and cell growth, based on our present data, is depicted in Fig. 10 . Covalent attachment of carbohydrates at one or more sites of the receptor proteins seems to be critical for the transport of IGF-1R to the cell membrane. If this modification is prevented the IGF-1 receptor proteins retain in the ER or Golgi. We provide evidence that MVA through regulating the rate of N-linked glycosylation is limiting for the translocation of IGF-1R from the intracellular compartment (ER and Golgi) to the cell surface. The mechanism by which MVA is limiting for N-linked glycosylation is that intermediates in the metabolism of MVA serve as precursors in the biosynthesis of dolichylphosphate. It was also confirmed in our experiments that inhibition of HMG-CoA reductase resulted in a rapid and substantial suppression of dolichyl-phosphate synthesis. Only newly synthesized dolichyl-phosphate has in fact been shown to be involved in N-linked glycosylation (37, 38) .
N-Linked glycosylation has been shown to be carried out on all proteins that are to be transported to the cell membrane (5, 39) . The core structure of the oligosaccharide complex is commonly composed of two N-acetyl-GlcN molecules, nine mannose and three glucose residues. Dolichyl-phosphate acts as a membrane-bound carrier of this complex inside the ER and makes it available to an oligosaccharyl transferase, which couples it to asparagine residues of de novo synthesized proteins. Only sites containing Asn-X-Thr/Ser sequences (X is any amino acid with the exception of proline) are recognized by the transferase (6, 40) . Since N-linked glycosylation occurs cotranslationally (6, 33, 34) only newly synthesized proteins are modified in this manner. In the present study we demonstrate that N-linked glycosylation of IGF-1R was efficiently blocked upon inhibition of HMG-CoA reductase, and also that the amount of de novo synthesized IGF-1R proteins at the cell surface was drastically decreased. In fact the expression of de novo synthesized IGF-1R proteins at the cell membrane correlated well with the MVAdependent changes in IGF-1 binding. This strongly suggests that the MVA-controlled translocation of newly synthesized and glycosylated receptors plays a pivotal role in the expression of functional IGF-1 binding sites.
In glycoproteins the carbohydrate moieties attached to the asparagine residues serve several and different specific purposes. For instance, N-linked glycosylation may prevent intracellular protein aggregation in the ER and may in addition be required for correct folding and cleavage of the precursor proteins. The N-linked oligosaccharides may also be needed for the direction of proteins through different compartments of the Golgi network in which they are further processed before the subsequent translocation to the cell surface (39) . Deficiency in N-linked glycosylation at certain glycosylation sites may therefore result in incorrect protein folding, suppressed efficiency and decreased rate of intracellular glycoprotein transport, or impaired protein function. Experiments with glycosylation site mutations of transfected cDNA of the insulin receptor suggest that the first four glycosylation sites of the ␣ subunit have to be glycosylated for the subsequent intracellular transport of de novo synthesized receptor proteins (26) . When these four glycosylation sites, due to mutations, were not glycosylated, the proteins were retained in the ER (26) . These data taken together with the fact that a large homology exists between insulin-R and IGF-1R (11) suggest that translocation-specific glycosylation sites also exist in IGF-1R. On the other hand, N-linked glycosylation is not critical for the translocation of all glycoproteins destined for the cell membrane. For example, glycosylation is not required for the export of the apoprotein B of the low density lipoprotein (41), the acetylcholine receptors (42) , muscarinic receptors (43), and rhodopsin in retinal disk membranes (44) . As was also shown in our experiments, inhibition of HMG-CoA reductase only caused a limited decrease in the total amount of de novo synthesized proteins located at the cell membrane. This indicates that glycoproteins on the whole are only slightly inhibited in their translocation to the cell surface.
The link between HMG-CoA reductase and IGF-1R expression raises the possibility that a deregulated control of MVA synthesis may contribute to uncontrolled growth of certain malignant cells. It is known that the level of dolichyl-phosphate and N-linked glycosylation is increased in malignant cells and tissues (45) . The increase in the dolichyl-phosphate synthesis might, at least partially, be a result of the uncontrolled regulation of HMG-CoA reductase which has been proven to be a unique and characteristic feature of malignant cells (2) . An increased biosynthesis of dolichyl-phosphate may also be due to a changed metabolism of MVA. This has been shown to be the case in the human lung adenocarcinoma cell line A459 in which 40% of the activity of HMG-CoA reductase was devoted to nonsterol products, compared to 15-20% in normal fibroblasts (46) . An increased N-linked glycosylation, due to an up-regulated dolichyl-phosphate biosynthesis, may contribute to an overexpression of growth factor receptors or other functional molecules at the tumor cell membranes. The IGF-1 signaling pathway has been shown to be of particular functional importance for melanoma cells, the cell surface of which contains abundant IGF-1R molecules (31) . If IGF-1R was blocked by antibodies or antisense oligonucleotides, growth and motility (47, 48) as well as tumorigenicity (31) of cultured melanoma cells were inhibited. Our present study also provides evidence that MVA is limiting for expression of IGF-1R in other malignant cell types. Therefore our results may offer a novel pharmacological approach to controlling malignant cell growth. This would be envisaged in particular against the group of malignant tumors in which uncontrolled growth and tumor progression are dependent on an overexpression of functional growth factor receptors at the cell surface.
